Activation of the RIG-I pathway during kinase inhibitor therapy was found to significantly reduce tumor size by inducing inflammatory and pro-apoptotic responses that synergize with kinase inhibitors to reduce depleted CD8+ T cells (Bragelmann et al., 2021). Here, RIGI is linked to neoplasm.